Recherche - Archive ouverte HAL Accéder directement au contenu

Filtrer vos résultats

8 Résultats
authFullName_s : E. Maillard

PO-0702: Phase I trial evaluating panitumumab in combination with chemoradiotherapy for anal cancers

V. Vendrely , C. Lemanski , E. Le Prise , E. Maillard , X. Mirabel et al.
ESTRO 36, May 2017, Vienne, Austria. , Radiotherapy and Oncology, 123 (Supplement 1), pp.S367 - S368, 2017, ESTRO 36, May 5-9, 2017, Vienna, Austria. ⟨10.1016/S0167-8140(17)31139-8⟩
Poster de conférence hal-01685153v1

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

C. Lepage , M. Phelip , L. Cany , E. Maillard , A. Lievre et al.
41st Congress of the European-Society-for-Medical-Oncology (ESMO), Oct 2016, Copenhague, Denmark. pp.483P, ⟨10.1093/annonc/mdw370.31⟩
Communication dans un congrès hal-01507441v1

Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20

T. Aparicio , O. Bouché , E. Francois , E. Maillard , S. Kirscher et al.
41st Congress of the European-Society-for-Medical-Oncology (ESMO), Oct 2016, Copenhague, Denmark. ⟨10.1093/annonc/mdw370.131⟩
Communication dans un congrès hal-01524852v1

PFOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial

J-B. Bachet , O. Lucidarme , C.B. Levache , E. Maillard , J.L. Raoul et al.
the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. pp.505P, ⟨10.1093/annonc/mdx393.031⟩
Communication dans un congrès hal-01632415v1

609TiPPRODIGE 50 - ASPIK French: French double blind randomised study of aspirin versus placebo in resected stage III or high risk stage II colon cancer with PIK3CA mutation

P. Michel , T. André , V. Boige , T. Aparicio , E. Maillard et al.
the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. ⟨10.1093/annonc/mdx393.134⟩
Communication dans un congrès hal-01632463v1

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results

T. Aparicio , O. Bouché , J. Taieb , E. Maillard , S. Kirscher et al.
Annals of Oncology, 2018, 29 (1), pp.133-138. ⟨10.1093/annonc/mdx529⟩
Article dans une revue hal-01699429v1
Image document

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD

T. Aparicio , A. Darut-Jouve , F. Khemissa Akouz , C. Montérymard , P. Artru et al.
Journal of geriatric oncology, 2020, ⟨10.1016/j.jgo.2020.04.001⟩
Article dans une revue hal-02901884v1

Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22)

M. Karoui , A. Rullier , C. Mariette , E. Maillard , A. Bardier et al.
the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. pp.476O, ⟨10.1093/annonc/mdx393.003⟩
Communication dans un congrès hal-01632311v1